Characterizing mucociliary clearance in young children with cystic fibrosis.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
14
08
2020
accepted:
18
02
2021
revised:
10
02
2021
pubmed:
24
3
2021
medline:
12
4
2022
entrez:
23
3
2021
Statut:
ppublish
Résumé
This research characterized mucociliary clearance (MCC) in young children with cystic fibrosis (CF). Fourteen children (5-7 years old) with CF underwent: two baseline MCC measurements (Visits 1 and 2); one MCC measurement approximately 1 year later (Visit 3); and measurements of lung clearance index (LCI), a measure of ventilation inhomogeneity. Median (range) percent MCC through 60 min (MCC60) was similar on Visits 1 and 2 with 11.0 (0.9-33.7) and 12.8 (2.7-26.8), respectively (p = 0.95), and reproducible (Spearman Rho = 0.69; p = 0.007). Mucociliary clearance did not change significantly over 1 year with median percent MCC60 on Visit 3 [12.8 (3.7-17.6)] similar to Visit 2 (p = 0.58). Lower percent MCC60 on Visit 3 was significantly associated with higher LCI scores on Visit 3 (N = 14; Spearman Rho = -0.56; p = 0.04). Tests of MCC were reproducible and reliable over a 2-week period and stable over a 1-year period in 5-7-year-old children with CF. Lower MCC values were associated with increased ventilation inhomogeneity. These results suggest that measurements of MCC could be used in short-term clinical trials of interventions designed to modulate MCC and as a new, non-invasive test to evaluate early lung pathology in children with CF. This is the first study to characterize mucociliary clearance (MCC) in children with cystic fibrosis (CF) who were 5-7 years old. Measurements of mucociliary clearance were reproducible and reliable over a 2-week period and stable over a 1-year period. Variability in MCC between children was associated with differences in ventilation homogeneity, such that children with lower MCC values had increased ventilation inhomogeneity. These results suggest that measurements of MCC could be used in short-term clinical trials of interventions designed to modulate MCC and as a new, non-invasive test to evaluate early lung pathology in children with CF.
Sections du résumé
BACKGROUND
This research characterized mucociliary clearance (MCC) in young children with cystic fibrosis (CF).
METHODS
Fourteen children (5-7 years old) with CF underwent: two baseline MCC measurements (Visits 1 and 2); one MCC measurement approximately 1 year later (Visit 3); and measurements of lung clearance index (LCI), a measure of ventilation inhomogeneity.
RESULTS
Median (range) percent MCC through 60 min (MCC60) was similar on Visits 1 and 2 with 11.0 (0.9-33.7) and 12.8 (2.7-26.8), respectively (p = 0.95), and reproducible (Spearman Rho = 0.69; p = 0.007). Mucociliary clearance did not change significantly over 1 year with median percent MCC60 on Visit 3 [12.8 (3.7-17.6)] similar to Visit 2 (p = 0.58). Lower percent MCC60 on Visit 3 was significantly associated with higher LCI scores on Visit 3 (N = 14; Spearman Rho = -0.56; p = 0.04).
CONCLUSIONS
Tests of MCC were reproducible and reliable over a 2-week period and stable over a 1-year period in 5-7-year-old children with CF. Lower MCC values were associated with increased ventilation inhomogeneity. These results suggest that measurements of MCC could be used in short-term clinical trials of interventions designed to modulate MCC and as a new, non-invasive test to evaluate early lung pathology in children with CF.
IMPACT
This is the first study to characterize mucociliary clearance (MCC) in children with cystic fibrosis (CF) who were 5-7 years old. Measurements of mucociliary clearance were reproducible and reliable over a 2-week period and stable over a 1-year period. Variability in MCC between children was associated with differences in ventilation homogeneity, such that children with lower MCC values had increased ventilation inhomogeneity. These results suggest that measurements of MCC could be used in short-term clinical trials of interventions designed to modulate MCC and as a new, non-invasive test to evaluate early lung pathology in children with CF.
Identifiants
pubmed: 33753897
doi: 10.1038/s41390-021-01453-2
pii: 10.1038/s41390-021-01453-2
pmc: PMC8455702
mid: NIHMS1676943
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
612-620Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001079
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128475
Pays : United States
Organisme : NIEHS NIH HHS
ID : R21 ES023384
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL080396
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL140039
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL129925
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL130938
Pays : United States
Informations de copyright
© 2021. The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc.
Références
Hodson, M. E., Geddes, D. & Bush, A. Cystic Fibrosis 3rd edn (Hodder Arnold, 2007).
Matsui, H. et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95, 1005–1015 (1998).
doi: 10.1016/S0092-8674(00)81724-9
Matsui, H. et al. Reduced three-dimensional motility in dehydrated airway mucus prevents neutrophil capture and killing bacteria on airway epithelial surfaces. J. Immunol. 175, 1090–1099 (2005).
doi: 10.4049/jimmunol.175.2.1090
Ratjen, F. & Doring, G. Cystic fibrosis. Lancet 361, 681–689 (2003).
doi: 10.1016/S0140-6736(03)12567-6
Davis, P. B., Drumm, M. & Konstan, M. W. Cystic fibrosis. Am. J. Respir. Crit. Care Med. 154, 1229–1256 (1996).
doi: 10.1164/ajrccm.154.5.8912731
Laube, B. L. et al. Changes in mucociliary clearance over time on children with cystic fibrosis. Pediatr. Pulmonol. https://doi.org/10.1002/ppul.24858 (2020).
doi: 10.1002/ppul.24858
pubmed: 32427408
pmcid: 7674244
Laube, B. L., Sharpless, G., Benson, J., Carson, K. A. & Mogayzel, P. J. Jr. Mucus removal is impaired in children with cystic fibrosis who have been infected by Pseudomonas aeruginosa. J. Pediatr. 164, 839–845 (2014).
doi: 10.1016/j.jpeds.2013.11.031
Bennett, W. et al. Multisite comparison of mucociliary and cough clearance measures using standardized methods. J. Aerosol Med. Pulm. Drug Deliv. 26, 157–164 (2013).
doi: 10.1089/jamp.2011.0909
Miller, M. R. et al. ATS/ERS Task Force. Standardisation of spirometry. Eur. Respir. J. 26, 319–338 (2005).
doi: 10.1183/09031936.05.00034805
Quanjer, P. H. et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur. Respir. J. 40, 1324–1343 (2012).
doi: 10.1183/09031936.00080312
Brody, A. S. et al. Reproducibility of a scoring system for computed tomography scanning in cystic fibrosis. J. Thorac. Imaging 21, 14–21 (2006).
doi: 10.1097/01.rti.0000203937.82276.ce
Robinson, P. D. et al. Consensus statement for inert gas washout measurement using multiple- and single- breath tests. Eur. Respir. J. 41, 507–522 (2013).
doi: 10.1183/09031936.00069712
Davies, J. C., Cunningham, S., Alton, E. W. & Innes, J. A. Lung clearance index in CF: a sensitive marker of lung disease severity. Thorax 63, 96–97 (2008).
doi: 10.1136/thx.2007.082768
Aurora, P. et al. Multiple-breath washout as a marker of lung disease in preschool children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 171, 249–256 (2005).
doi: 10.1164/rccm.200407-895OC
Schaedel, C. et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr. Pulmonol. 33, 483–491 (2002).
doi: 10.1002/ppul.10100
Kraemer, R., Blum, A., Schibler, A., Ammann, R. A. & Gallati, S. Ventilation inhomogeneities in relation to standard lung function in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 171, 371–378 (2005).
doi: 10.1164/rccm.200407-948OC
Gustafsson, P. M., De Jong, P. A., Tiddens, H. A. & Lindblad, A. Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis. Thorax 63, 129–134 (2008).
doi: 10.1136/thx.2007.077784
Cutting, G. R. Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann. NY Acad. Sci. 1214, 57–69 (2010).
doi: 10.1111/j.1749-6632.2010.05879.x
Chalmers, J. D., Fleming, G. B., Hill, A. T. & Kilpatrick, D. C. Impact of mannose-binding lectin insufficiency on the course of cystic fibrosis: a review and meta-analysis. Glycobiology 21, 271–282 (2011).
doi: 10.1093/glycob/cwq161
Corvol, H., Cutting, G. R., Drumm, M. L., Knowles, M. R. & Strug, L. J. Genome-wide association meta-analysis in ~6,400 CF patients confirms previous findings and identifies new loci contributing to variation in lung disease. Pediatr. Pulmonol. 49, 271–272 (2014).
Kesimer, M. et al. Molecular organization of the mucins and glycocalyx underlying mucus transport over mucosal surfaces of the airways. Mucosal Immunol. 6, 379–392 (2013).
doi: 10.1038/mi.2012.81
Wright, F. A. et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat. Genet. 43, 539–546 (2011).
doi: 10.1038/ng.838
Blue, E. et al. Variation in cilia protein genes and progression of lung disease in cystic fibrosis. Ann. Am. Thorac. Soc. 15, 440–448 (2018).
doi: 10.1513/AnnalsATS.201706-451OC
Emond, M. J. et al. Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis. Nat. Genet. 44, 886–889 (2013).
doi: 10.1038/ng.2344
Evans, C. M. et al. The polymeric mucin Muc5ac is required for allergic airway hyperreactivity. Nat. Commun. 6, 6281 (2015).
doi: 10.1038/ncomms7281
Roy, M. G. et al. Muc5b is required for airway defense. Nature 505, 412–416 (2014).
doi: 10.1038/nature12807
Stock, C. J. et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 68, 436–441 (2013).
doi: 10.1136/thoraxjnl-2012-201786
Kamio, K. et al. Promoter analysis and aberrant expression of the MUC5B gene in diffuse panbronchiolitis. Am. J. Respir. Crit. Care Med 171, 949–957 (2005).
doi: 10.1164/rccm.200409-1168OC
Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).
doi: 10.1093/nar/gkx1153
Mayer-Hamblett, N. et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. Am. J. Respir. Crit. Care Med. 175, 822–828 (2007).
doi: 10.1164/rccm.200609-1354OC
Laube, B. L., Carson, K. A., Sharpless, G., Paulin, L. M. & Hansel, N. N. Mucociliary clearance in former tobacco smokers with both chronic obstructive pulmonary disease and chronic bronchitis and the effect of Roflumilast. J. Aerosol Med. Pulm. Drug Deliv. 32, 189–199 (2019).
doi: 10.1089/jamp.2018.1459
Newman, S. et al. Standardization of techniques for using planar (2D) imaging for aerosol deposition assessment of orally inhaled products. J. Aerosol Med. Pulm. Drug Deliv. 25, S10–S28 (2012).
doi: 10.1089/jamp.2012.1Su4
Fleiss, J. L. In The Design and Analysis of Clinical Experiments 264–281 (Wiley, 1999).
Henke, M. O. et al. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am. J. Respir. Crit. Care Med. 175, 816–821 (2007).
doi: 10.1164/rccm.200607-1011OC
Henderson, A. G. et al. Cystic fibrosis airway secretions exhibit mucin hyperconcentration and increased osmotic pressure. J. Clin. Investig. 124, 3047–3060 (2014).
doi: 10.1172/JCI73469